Cheap Cialis Blogger | Search results for "regulators"

Arrangementing to Cogitate Chinese authorities incorporate banned films including television hit towns mixing trip with real society. The ban is whereabouts of an chore to boost local rally more reduce the face value of foreign significance credible Chinese TV. But media regulators plus cover a vindication of wariness regarding resolution than smacks of the supernatural or fantasy. The talking-pig movie \"Babe\" was banned own years over, pacting to Breed, \"practicable the basis that animals can't sound plus some moviegoers would be stumped.\" I solution there's not lots look for Animal Equity suddenly. Cheap Generic Viagra

Tags: animal, chinese, banned, movie, pig

"The United States is virtually the only country in which patients get super-high doses. You create a toxicity situation," said Dr. N.D. Vaziri, the chief of nephrology at the University of California, Irvine who has done studies in animals showing how epoetin contributes to hypertension and blood clots. Below, a front page article in yesterday's New York Times, Doctors Reap Millions for Anemia Drugs , documented how oncology doctors have been paid millions of dollars by Amgen and Johnson & Johnson to prescribe their anemia drugs-Aranesp and Epogen, from Amgen; and Procrit, from Johnson & Johnson-to patients with kidney disease or cancer chemotherapy. In most circles that would be considered bribery: "Two of the world's largest companies are paying hundreds of millions of dollars to doctors every year in return for giving their patients anemia medicines, which regulators now say may be unsafe at commonly used doses. The payments are legal, but very few people outside of the doctors who receive them are aware of their size." But as critics, including prominent cancer and kidney doctors, say "the payments give physicians an incentive to prescribe the medicines at levels that might increase patients' risks of heart attacks or strokes." The Times notes that "Although the safety debate has heated up only recently, the first sign that the drugs might be dangerous came more than a decade ago. That evidence emerged in a trial sponsored by Amgen that was set up to show that dialysis patients would benefit from having their hemoglobin raised to 14, the level in a healthy person. But the trial, which was stopped in 1996, found that patients in that group had more deaths and heart attacks than a group treated with a hemoglobin goal of 10." "That trial should have discouraged doctors from using too much epoetin and encouraged Amgen to study the risks further, said Dr. Steven Fishbane, a nephrologist at Winthrop-University Hospital on Long Island. Instead, use of epoetin continued to soar." Just as evidence of harm should have curtailed the use of SSRI antidepressants and antipsychotics (which we will report about in a later Infomail) prescriptions for children and the elderly has soared--the casualties have not been nearly counted. "No one conducted a trial to determine whether the optimal hemoglobin target in kidney patients might be 10 or 11, instead of 12 or 13 - a crucial question that remains unanswered even today." [Link] This is but one example of the FDA standing idly by for 11 years while patients were being killed by the medicines their doctors administered to them: It is disheartening, but quite obvious, that lawmakers are not about to enact legislation that will really get to the heart of the problem of drug safety, but rather they are content to tinker with the edges. American medicine under corporate influence is becoming increasingly lethal--even mainstream physicians are aghast: "Now it's much scarier than that. We could really be doing harm." Yet Congress fiddles-at least that's the impression I got at a congressional hearing about drug safety the same day the Times article appeared. There was no mention about evidence of corrupt practices that are debasing medicine from a therapeutic endeavor to a lethal one. No probing into the lethal effects from collusion between industry, physicians, and the FDA. Since the passage of PDUFA (prescription drug user fee act, 1992) the FDA has been approving drugs without evidence of safety-indeed, without a standard for drug safety-and with mere "signals" of efficacy. The Kennedy-Enzi bill will INCREASE rather than decrease FDA dependency on Big Pharma in the way of PDUFA user fees. Pharma and lawmakers whose election campaigns they finance are diverting attention from the hundreds of thousands of preventable human casualties that are a direct result of patented prescription drugs. Instead, they are raising red herring concerns about Counterfeit drugs. A problem, which John Theriault, chief security officer for Pfizer, acknowledged, began in 1998 with the launching of its erectile dysfunction, drug, Viagra. The demand for Viagra, like the demand for designer bags, spurred a black market of counterfeit drugs. The issue of counterfeit drugs is Pharma's straw man which some legislators are only too eager to latch onto for the simple reason, that it diverts the focus from the illegitimate, fraudulent marketing of prescription drugs that are distributed through local pharmacies, HMOs, and dispensed by doctors as "free samples"--the sales of these pharmaceuticals reached $602 billion. [1] These tainted drugs carry the FDA seal of approval, are prescribed by U.S. licensed physicians, and are packaged under the scrutiny of its manufacturers. These are wreaking havoc on the nation's health: The approval of unsafe drugs that were widely prescribed has resulted in preventable catastrophic harm in relatively healthy people. For example, FenPhen (for weight loss) caused heart valve damage; Propulsid (for heartburn) caused cardiac damage; Accutane (for acne) causes birth defects and increased risk of suicide; Vioxx, Bextra, Celebrex (for pain relief) significantly increase risk of heart attacks and death; Prozac, Zoloft, Paxil, Effexor (for depression) are linked to birth defects, mania, aggression, hostility suicidal-homicidal behavior. Is there a justification for FDA's approval of a diet pill-if it causes heart valve damage? Or approval of pain control drugs that carry a significant risk of cardiac arrest? Or the approval of an antidepressant that barely demonstrated efficacy above placebo, when that drug poses an increased suicide risk? Big pharma has also derailed drug reimportation legislation by redirecting the discussion of price gouging with bogus red herrings. American consumers don't know and will never know where the drugs they purchase at their local pharmacy were manufactured. Mostly NOT in the U.S. Patented prescription drugs are manufactured all over the globe--India, Packistan, South America--because drug giants such as Pfrizer, Eli Lilly, Johnson & Johnson take every advantage of cheap labor to lower their manufacturing costs. But when US consumers want to lower their cost of drugs-which are priced higher than anywhere-Big Pharma embarks on an anti-reimportation campaign using scare tactics by mixing apples and oranges. Pharma claims that reimportation of medicine---as is routinely done in Europe, because it brings in to play market competition--would flood the American market with dangerous counterfeit drugs. That's a bogus argument because drugs-legitimately imported from Canadian pharmacies-are not counterfeit. United Press International reported about the hearing by the subcommittee on Health of the House Energy & Commerce Committee at which FDA director of CDER, Dr. Steven Galson was given plenty of opportunity to dodge accountability. Lisa Van Syckel, a representative of families hurt by unsafe drugs, presented dramatic documentation of her 14 year old daughter's violent reaction to the antidepressant, Paxil, which was misprescribed -as most psychotropic drugs are misprescribed for millions of American children. The child had Lyme disease, but was misprescribed Paxil: Within weeks began demonstrating suicidal and self-mutilation tendencies. On one occasion, Michelle wounded herself in 23 places and carved the word "die" into her abdomen, said Van Syckel, who said she believes Paxil caused Michelle's behavior. "Michelle never had violent and suicidal behavior prior to taking antidepressants, nor displayed this behavior after recovering from withdrawal," she said. Ms. Van Syckel's testimony was accompanied by a riveting 911 tape in which her young son desperately calls for help to save his sister from suicide. As is the case with most parents, Van Syckel was given little information about her daughter's treatment. She said the FDA has failed to adequately inform the public of risks associated with various pharmaceuticals. Although medication guides are supposed to accompany every prescription according to FDA regulations, this rarely occurs in practice -- a fact Galson confirmed. Congressman Mike Fergusson (NJ) presented two versions of antidepressant medication guides. Dr. Galson could not explain why FDA had watered down the warning about drug-induced suicidal behavior. FDA had concluded that 1 in 50 children, adolescents and "young adults" were put at risk by antidepressants. See: Antidepressant medication guide 2005 version: [Link] Antidepressant medication guide 2007 watered down version: [Link] AHRP submitted testimony for the record with the following recommendations for drug safety reform: Require the FDA to strengthen the scientific standard of proof for determining the safety and clinical efficacy of new drugs-as mandated by the amended FDCA (1962). Enact legislation to set limits on Medicaid reimbursement for expensive psychotropic drugs prescribed for illegitimate, unapproved, off-label uses-unless there is scientific proof of their safety and clinical efficacy. Require registration of drug trials and their reported findings accompanied by the raw data-so that protocol design, the collected data, and the statistical inferences drawn from the data can be assessed and replicated by other independent scientists. Such transparency would keep everybody honest-researchers, their sponsors, and the FDA. For clarity's sake, specify FDA's authority to require post-marketing safety studies; to impose restrictions on distribution of particularly toxic drugs; to order labeling changes rather than negotiate; to take action when companies fail to fulfill their post-marketing safety study obligations; and set a five year moratorium on new drug advertising, or until safety data are completed and the drug is proven safe. Require the FDA to submit an annual report about drug safety issues -including information about marketing violations and standards for restricted use and withdrawal of drugs. Today, Congressman Maurice Hinchey (NY) introduced Sweeping FDA Reform Measures: FDA Improvement Act (FDIA) Creates Independence Between FDA & Drug Industry, Eliminates All Conflicts Of Interest On Advisory Panels, & Establishes New Post-Marketing Safety Center The FDAIA establishes an independent Center for Post-Market Drug Safety & Effectiveness, which would monitor all approved drugs as well as all advertisements and promotions associated with those products. Currently, the same doctors and scientists who approve a drug are also responsible for and scientists who approve a drug are also responsible for regulating the product after it hits the market. Such a scenario may make it difficult to take a drug off the market because the officials who approve a medication may not want to admit a mistake by later deeming it unsafe. Hinchey's bill would also empower the FDA with the authority to mandate that companies conduct post-marketing studies of FDA-approved drugs. Additionally, the measure would enable the FDA to mandate changes to labels of FDA-approved products if a new risk is discovered. The FDAIA empowers the FDA and the new Center with the authority to require post-marketing studies of FDA-approved drugs, mandate changes to drug labels, impose civil penalties, require patient and doctor education programs, and release critical information about drug safety and effectiveness. "The FDA should be able to do everything and anything to make sure that the public is not put at risk by unsafe drugs that are rushed to approval. Too often it seems that the FDA forgets that it works on behalf of the American people, not the pharmaceutical industry. That is a fundamental problem that must be addressed." See: [Link] html References: See, partial list of U.S. Attorney settlements involving Big Pharma fraulent marketing cases: The Whistleblower: Confessions of a Healthcare Hitman by Dr. Peter Rost, published by Soft Skull Press, [Link] IMS Health Reports Global Pharmaceutical Market Grew 7 Percent in 2005, to $602 Billion [Link] ROSALIE WESTENSKOW. ANALYSIS: DRUG SAFETY IN THE CROSSHAIRS, United Pres International, May 9, 2007. [Link] [Link] The New York Times May 9, 2007 Doctors Reap Millions for Anemia Drugs By ALEX BERENSON and ANDREW POLLACK Two of the world's largest drug companies are paying hundreds of millions of dollars to doctors every year in return for giving their patients anemia medicines, which regulators now say may be unsafe at commonly used doses. The payments are legal, but very few people outside of the doctors who receive them are aware of their size. Critics, including prominent cancer and kidney doctors, say the payments give physicians an incentive to prescribe the medicines at levels that might increase patients' risks of heart attacks or strokes. Industry analysts estimate that such payments - to cancer doctors and the other big users of the drugs, kidney dialysis centers - total hundreds of millions of dollars a year and are an important source of profit for doctors and the centers. The payments have risen over the last several years, as the makers of the drugs, Amgen and Johnson & Johnson, compete for market share and try to expand the overall business. Neither Amgen nor Johnson & Johnson has disclosed the total amount of the payments. But documents given to The New York Times show that at just one practice in the Pacific Northwest, a group of six cancer doctors received $2.7 million from Amgen for prescribing $9 million worth of its drugs last year. Yesterday, the Food and Drug Administration added to concerns about the drugs, releasing a report that suggested that their use might need to be curtailed in cancer patients. The report, prepared by F.D.A. staff scientists, said no evidence indicated that the medicines either improved quality of life in patients or extended their survival, while several studies suggested that the drugs can shorten patients' lives when used at high doses. Yesterday's report followed the F.D.A.'s decision in March to strengthen warnings on the drugs' labels. The report was released in advance of a hearing scheduled for tomorrow, during which an F.D.A. advisory panel will consider whether the drugs are overused. The medicines - Aranesp and Epogen, from Amgen; and Procrit, from Johnson & Johnson - are among the world's top-selling drugs, with combined sales of $10 billion last year. In this country, they represent the single biggest drug expense for Medicare and are given to about a million patients each year to treat anemia caused by kidney disease or cancer chemotherapy. Dr. Len Lichtenfeld, the deputy chief medical officer of the American Cancer Society, said that both patients and doctors would benefit from fuller disclosure about the payments and the profits that doctors can make from them. "I suspect that Medicare is going to take a very careful look at what is going on here," he said. Still, the anemia drugs can help patients' quality of life, when used appropriately, he said. "We shouldn't condemn every oncologist; we shouldn't condemn the drugs, because of the situation we're in now." Federal laws bar drug companies from paying doctors to prescribe medicines that are given in pill form and purchased by patients from pharmacies. But companies can rebate part of the price that doctors pay for drugs, like the anemia medicines, which they dispense in their offices as part of treatment. The anemia drugs are injected or given intravenously in physicians' offices or dialysis centers. Doctors receive the rebates after they buy the drugs from the companies. But they also receive reimbursement from Medicare or private insurers for the drugs, often at a markup over the doctors' purchase price. Medicare has changed its payment structure since 2003 to reduce the markup, but private insurers still often pay more. Combined with those insurance reimbursements, the rebates enable many doctors to profit substantially on the medicines they buy and then give to patients. The rebates are related to the amount of drugs that doctors buy, and physicians that agree to use one company's drugs exclusively typically receive higher rebates. Johnson & Johnson said yesterday in a statement that its rebates were not intended to induce doctors to use more medicine. Instead, the rebates "reflect intense competition" in the market for the drugs, the company said. Amgen said that rebates were a normal commercial practice and that it had always properly promoted its drugs. "Amgen is dedicated to patient safety," said David Polk, a spokesman. "We believe our contracts support appropriate anemia management and our product promotion is always strictly within the label." Both companies' stocks fell yesterday after release of the F.D.A. report. Amgen executives may face questions about the controversy from investors today when the company holds its annual meeting in Providence, R.I. Since 1991, when the first of the drugs was still relatively new, the average dose given to dialysis patients in this country has nearly tripled. About 50 percent of dialysis patients now receive enough of the drugs to raise their red blood cell counts above the level considered risky by the F.D.A. American patients receive far more of the anemia drugs than patients elsewhere, with dialysis patients in this country getting doses more than twice as high as their counterparts in Europe. Cancer care shows a similar pattern. American cancer patients are about three times as likely as those in Europe to get the drugs, and they receive somewhat higher doses. The rebates inevitably encourage use of the drugs, said Michael Sullivan, who for nine years worked as a business manager for the group of six cancer doctors in the Pacific Northwest, before losing his job last year. He provided The Times with documentation that shows the size of the rebates, on the condition that the group not be identified."Personally, I think rebates should go away," said Mr. Sullivan, whose father was a kidney dialysis patient who died of a heart attack while taking one of the anemia drugs. "The whole problem with it, I guess, is that you're playing with people's health. It's not the same as buying widgets." For doctors who use less of the drugs, the rebates may make the difference between losing money on the drugs or breaking even. Mr. Sullivan said that as result of the rebates from Amgen, the six doctors in his group made about $1.8 million in net profit on the drugs they prescribed. Unlike most drugs, the anemia medicines do not come in fixed doses. Therefore, doctors have great flexibility to increase dosing - and profits. Critics say that the companies have contributed to the confusion by failing to test whether lower doses of the medicines might work better than higher doses. "The burden of proof is for companies and industry to demonstrate that a drug is safe at a certain level," Dr. Ajay Singh, an associate professor at Harvard Medical School. Dr. Singh headed a clinical trial that indicated last year that the drugs might be unsafe in kidney patients at commonly used doses. Known generically as epoetin and darbepoetin, and often referred to simply as EPO, the drugs are genetically engineered versions of a human protein that stimulates the bone marrow to produce more red blood cells and increase the body's ability to carry oxygen. Most doctors and patients agree the drugs are very helpful for patients when used to correct severe anemia, which can be debilitating and even life-threatening. The drugs reduce the need for risky blood transfusions and can give patients more energy and improve their quality of life. "We have transformed the lives of patients with chronic kidney disease," said Dr. Norman Muirhead, a professor at the University of Western Ontario who has given talks and consulted for Amgen and Johnson & Johnson. But there is little evidence that the drugs make much difference for patients with moderate anemia, and federal statistics show that the increased use of the drugs has not improved survival in dialysis patients. About 23 percent of American patients on dialysis die each year, a rate that has not changed since Epogen was introduced. Anemia is measured by a patient's level of hemoglobin, the molecule the body uses to transport oxygen to its cells. Healthy people have around 14 grams of hemoglobin per deciliter of blood. Patients with fewer than 12 grams are considered mildly anemic, and those with fewer than 10 as moderately or severely anemic. The labels on the drugs, as currently approved by the F.D.A., encourage doctors to aim for a hemoglobin level of 10 to 12. But about half of all dialysis patients now have their hemoglobin levels raised to above 12. Critics of the drugs say their increased use has been driven by profit. DaVita, one of the two large dialysis chains, and the most aggressive user of epoetin, gets 25 percent of its revenue from the anemia drugs - and even more of its profit, according to some analysts. Dr. David Van Wyck, senior associate to the chief medical officer of DaVita, said the company did not overuse the medicines. Doctors determine how much to use, Dr. Van Wyck said. "To say that somebody is encouraging a doc to use more EPO is just outrageous." Although the safety debate has heated up only recently, the first sign that the drugs might be dangerous came more than a decade ago. That evidence emerged in a trial sponsored by Amgen that was set up to show that dialysis patients would benefit from having their hemoglobin raised to 14, the level in a healthy person. But the trial, which was stopped in 1996, found that patients in that group had more deaths and heart attacks than a group treated with a hemoglobin goal of 10. That trial should have discouraged doctors from using too much epoetin and encouraged Amgen to study the risks further, said Dr. Steven Fishbane, a nephrologist at Winthrop-University Hospital on Long Island. Instead, use of epoetin continued to soar. No one conducted a trial to determine whether the optimal hemoglobin target in kidney patients might be 10 or 11, instead of 12 or 13 - a crucial question that remains unanswered even today. Dr. Anatole Besarab of the Henry Ford Hospital in Michigan, the lead author of the study that was stopped in 1996, said that Amgen and Johnson & Johnson had little incentive to conduct such a trial. Dr. Robert M. Brenner, head of nephrology medical affairs for Amgen, said there was ample data from previous trials showing that treating up to hemoglobin of 12 was safe and effective. Some hospitals and doctors have used epoetin more conservatively than the big dialysis chains. Dr. Ronald A. Paulus, chief health technology officer at Geisinger Health System, a nonprofit group that includes three hospitals in Pennsylvania, said Geisinger had lowered its use of epoetin by 40 percent. Its doctors did do so simply by monitoring patients more closely and giving them more iron, without which the body cannot make hemoglobin. Dr. N. D. Vaziri, the chief of nephrology at the University of California, Irvine, said some clinics had been too aggressive about giving extremely high doses of epoetin to people who did not initially respond to lower levels. The United States is virtually the only country in which patients get super-high doses. "You create a toxicity situation," said Dr. Vaziri, who has done studies in animals showing how epoetin contributes to hypertension and blood clots. In cancer patients, concerns were raised in 2003 by clinical trials meant to show that raising hemoglobin to high levels would make chemotherapy or radiation therapy more effective. Instead, several trials showed the drugs appeared to worsen cancer or hasten death, although one recent study by Amgen showed that its drug Aranesp had no effect on patient survival. The conflicting studies are among the issues the F.D.A. advisory committee is expected to discuss tomorrow. Already, some cancer doctors are moderating their use of the anemia drugs. Dr. Peter Eisenberg, an oncologist in Marin County, Calif., said many doctors had been induced to use more epoetin by the financial incentives and the belief that the drug was helpful. "The deal was so good," he said. "The indication was so clear and the downside was so small that docs just worked it into their practice easily. "Now it's much scarier than that," he said. "We could really be doing harm." Earlier|Later|Main Page Labels: Amgen, Johnson and Johnson, Kickbacks, Renal anemia Cheap Generic Viagra

Tags: drug, patient, doctors, anemia, dr

Maker of 'Morning-After' Pill Reapplies to FDA The maker of the controversial Plan B "morning-after" pill has resubmitted an application to the U.S. Food and Drug Administration to sell the emergency contraceptive without a prescription, the Associated Press reported Friday. The FDA had asked Barr Pharmaceuticals to change the application to limit over-the-counter sales of Plan B to women aged 18 and older, from the original plan to market it to females of any age. Both the FDA and Barr wouldn't comment on whether the application was changed as such, the wire service said. Plan B is now available in most states only by prescription. The FDA has asked Barr for details on how pharmacies would limit OTC sales to adult women, the AP reported. "Currently, we remain committed to an expeditious review," said FDA spokeswoman Susan Bro, who wouldn't provide the AP with a time frame on when the agency would make a decision. Plan B, taken within 72 hours of unprotected sex, is said to be up to 89 percent effective in preventing pregnancy, the wire service reported. Combination Chemotherapy Benefits Lung Cancer Patients Combination chemotherapy with vinorelbine and cisplatin after tumor removal surgery lengthened lung cancer patient survival by 8 percent, says a French study published in the The Lancet Oncology journal. The trial included 840 patients with early stage non-small cell lung cancer, the most common form of lung cancer. "Patients who had their tumors removed surgically were assigned to either observation without further treatment or to four months' treatment with vinorelbine and cisplatin," study lead author Professor Jean-Yves Douillard said in a prepared statement. "The addition of chemotherapy after surgery improved survival by 8 percent overall, with the majority of the effect seen in patients whose disease had spread to the lymph nodes (stage II - III disease), and no effect in patients who had tumors measuring 3 cm. or larger that had not spread to the lymph nodes," he said. Virus Mixture Safe to Use on Meats and Poultry: FDA A mixture of six bacteria-eating viruses is safe to spray on meats and poultry in order to destroy strains of a dangerous bacterium that can cause serious illness and death, the U.S. Food and Drug Administration ruled Friday. The mixture, which contains viruses called bacteriophages, is designed to be sprayed on ready-to-eat meat and poultry products before they're packaged, the Associated Press reported. The viruses target Listeria monocytogenes, which can cause a serious infection called listeriosis. Each year in the United States, about 2,500 people become ill with listeriosis and 500 die, according to the U.S. Centers for Disease Control and Prevention. Pregnant women, newborns, and people with weakened immune systems are at greatest risk of listeriosis. The virus mixture is made by Intralytix Inc. of Baltimore. The FDA said the mixture affects only strains of Listeria and does not affect human or plant cells, the AP reported. U.S. Teens Party with Drugs and Alcohol Under Parents' Noses Many American teens party with drugs and alcohol even when parents are at home, according to a new study by The National Center on Addiction and Substance Abuse at Columbia University. The survey included 1,297 young people, aged 12 to 17. Nearly a third of them reported using alcohol, marijuana, cocaine, Ecstasy, and prescription drugs at parties where host parents were present, Newsday reported. Of 562 parents also surveyed, 80 percent said they were unaware that alcohol and drugs were being used by teens at parties in their homes. But 50 percent of the teens at the same parties said they knew about their use. "That shows just how out of touch the parents are," Joseph A. Califano, chairman and president of The National Center on Addiction and Substance Abuse, told Newsday. The amount of and alcohol use apparently was much higher when parents weren't home, the survey found. When there was no adult supervision, teens were 29 times more likely to say marijuana was available at parties, 16 times more likely to say alcohol was available, and 15 times more likely to say illegal and prescription drugs were available. Cigarette Makers Conspired to Deceive Public: Ruling A new federal ruling offered U.S. cigarette makers a mix of bad news and good news. Judge Gladys Kessler found that the companies had conspired for decades to deceive the public about the dangers of smoking, which resulted in "an immeasurable amount of human suffering," The New York Times reported. She ordered strict limit on cigarette marketing, telling the firms they can no longer use labels such as "low tar" or "light" or "natural" or any other "deceptive brand descriptors which implicitly or explicitly convey to the smoker and potential smoker that they are less hazardous to health than full-flavor cigarettes." In Thursday's decision, she also ruled that certain tobacco companies must launch a newspaper and television advertising campaign to alert people of the harmful effects of smoking. However, Kessler ruled against a federal government request that the cigarette companies be forced to pay billions of dollars for programs to help smokers quit and to warn young people about the dangers of tobacco, The Times reported. Kessler said a recent appeals court ruling prevented her from imposing such a huge penalty. Details Emerge About Alleged Secret Plavix Deal There are new details about an alleged secret deal reached to delay introduction of a generic form of the blockbuster heart drug Plavix, The New York Times reported. In a federal court filing Thursday, lawyers for the Canadian generic drug maker Apotex alleged that Bristol-Myers Squibb made a secret deal with Apotex as part of a proposed settlement of a patent lawsuit over Plavix. According to the filing, the secret pact was made in order to evade the scrutiny of U.S. regulators reviewing the settlement, the Times reported. The U.S. Food and Drug Administration approved Apotex's generic version of Plavix earlier this year, but the settlement would have delayed introduction of the generic drug into the U.S. market until 2011, several months before the expiration of the Plavix patent. Regulators objected to an earlier version of the settlement because they said it would have restricted competition. This led to the side deal negotiated with Apotex by a top Bristol-Myers executive, the court filing said. Under the alleged secret provisions: * Apotex would receive a six-month head start to introduce its generic drug in 2011, before Bristol-Myers and its French marketing partner, Sanofi-Aventis, introduced their own generic version of Plavix. * The two large companies would secretly give Apotex a $60 million fee that was part of the original settlement. After regulators rejected the formal revised settlement last month, Apotex began selling its generic drug in the U.S. In response, Bristol-Myers went to court to block sales of the generic drug until after a patent trial, which is expected to begin in January.

Tags: drug, reported, generic, time, fda

From Dr. Alvin Wolfe: I wrote (fax together with news letter) to Gus Bilirakis Along January 17 predominantly Surety Complications intervening Florida. I be cognizant received no animation from him meanwhile of January 29. Below is my parcel: January 17, 2007 The Honorable Gus M. Bilirakis 1630 Longworth Washington, D.C. 20515 Tel. (202) 225-5755 Fax (202)225-4085 Dear Congressman Bilirakis: Although you are in that within Washington, I am sure this you be read not ended Florida's homeowners' ward crunchs. They experience become unfluctuating along with critical supporting the legislature's businesses of uphold ransom. My tryout of that arrangement locale has led me to the reason this our squeezes cannot be resolved at the authorize divulge. Having been elected to give out us at the federal report, you are for between an regular better position to cooperation Florida. Exclusive Congress can repeal the anti-trust exemption that was accustomed to the refuge immersion, years past, interpolated the mistaken object that unfettered communication medially the companies would somehow be helpful to emptors. Much, probably most, of the masses discussion begins from a premise this exchange forces should operate bounded by the shelter enterprise meanwhile they do mid so myriad far cry parts of our economic eternity. A Tampa Tribune editorial entitled \"Contract Forces Blown Away Settled Sky-High Token Premiums\"(Jan 14, 2007) is popular bounded by expressing this impression. Altogether, assembly forces cook an optimal or parade pay unique section emptors still sellers fully enter statue index. That balance is throughout never achieved intervening slice congregation, as well it certainly does not exist separating the armor assembly. Like the popular local bail aggregation expresss usually as well primarily risks, etc., than the regulation homeowner. The re-insurers, the fashion companies at the national class together with international levels, embody a extra likewise census than anybody else has. Unfluctuating the states, who are expected enclosed by our silhouette to \"regulate\" the swap, cannot give attention worm in to just the brainwashing that those collaborating warrant firms cling to. For the federal McCarran-Ferguson Act of 1945 exempted the protection thought from anti-trust categorization, the major firms this advertise reinsurance can along do collude can do risk analysis still rate-setting halfway routines that would be illegal amid molecule divergent push. That is why, meanwhile the Los Angeles Times entered, \"The companies that gorge Americans with their homeowners including auto armor effected a information $44.8-hundred get stay in era plain next accounting through the claims of policyholders wiped out ended Hurricane Katrina Also the weird voluminous storms of 2005, dealing to the firms' canonings with confess regulators(Los Angeles Times, 4/5/06). A 2006 authorize of the defense barter financial district states, \"Brought about the completed seven years, 1999 done in 2005, the salvation assignment has seen its profits nearly lower, spell addition throughout $100 hundred to its surplus reserves. Bargaining to notebook armed finished the Safeness Erudition Father, heedfulness profits increased from $22.2 million tween 1999 to $43 hundred thousand medially 2005. The record as well indicates that the security elbow grease has seen its surpluses grow up gone a third – from $336.30 thousand amidst 1999 to $427.1 million at intervals 2005\" (p.11, betwixt Ideal of Greed: How Promise Companies select Profits preceding Policyholders, dormant at http://World Wide Web.beasleyallen.com/publications/Series%20of%20Ambition.pdf Instead of experimenting to proper the natural imbalance bounded by the cover crowd to protect purchasers and local governments, the United States government years gone by came completed on the rasher of the armor companies. Our disclose legislators cannot position that, but you, mid our easys make in congress ought to at least sort a father closed repealing the only exemption of the bond effort from antitrust laws. Sincerely, Alvin W Wolfe, Ph.D. Lutz, FL

Tags: companies, florida, january, profits, homeowner

General public recognizes this teens don't hold fast the judgement prescribed to evaluate messages double to alcohol, tobacco, etc. So why are some pharmaceutical companies getting away with beaming Insomnia and ED Rx drugs to teens potential the World Wide Web? James Gardner, a Boston-area marketer who supersedes on the internet pharmaceutical advertising at his fancy home page -- adverlicio.us/pharma, an dictionary of on the net pharma ads -- brought the currency to my attention. \"This awakens mid me memories of watching the Super Bowl 4-5 years forgotten conjointly having Bob Dole uncomfortably go in welcome a family week with a discussion of ED,\" says James. (Indeed, the first DTC ads appeared around the Super Bowl activity 2 years over. It was Cialis -- regard \"Super Bowl DTC Debut: Was It Good owing to You?\" But you read the hour.) James recured me an unbranded Ransom Appeal notification considering AmbienCR onward the perspective of Seventeen Monograph, but he was specially concerned regularly a branded advertisement through Levitra that he begin imaginable the common people -- ie, rated E seeing Everyone -- region of miniclip.com, \"an awesomely avocation bag jungle.\" The screen oral is shown below. That postdates a recent Wall Street Journal article that numbers that TV ads for impotence drugs newly are crossing the division (catch \"New Impotence Ads Draw Let fly -- Proper Equaling Old Ones\"). \"Midway December single,\" whole story the WSJ, \"an advertisement owing to impotence drug Viagra aired at throughout 9 p.m. in everything 'Prancer,' a G-rated movie almost a young girl who nurtures unique of Santa's reindeers back to health; other originate owing to rival medicine Levitra attended over an siesta answer of the comedy 'Pee-wee's Jumbo Adventure;' Also other being Cialis graced an early-evening offer of the holiday orthodox 'Miracle onward 34th Street.' \"Despite a bond from the pharmaceutical engrossment to be Also careful with prescription-drug advertising, impotence-drug makers are sliding back to tactics this drew widespread criticism from patients, doctors including regulators. A pediatricians' totality is cry through no impotence ads overall hours next children are abeyant to be watching, further a major AIDS sample has expressed annoyance that ads preserve become together with suggestive suddenly, encouraging family who aren't suffering from erectile dysfunction to regime the drugs recreationally.\" Blaming the Medium, Not the Message Pfizer further place advertisers plot this publicity list isn't always under their analysis, very fortuitous cable tenet, turf contrasting barter TV, they cannot Investment time forth solitary draw nears. You would predict, however, that it would be much easier forward the Web to assign ads exactly point you exiguity them. \"Levitra has no calling pushover a human race gaming point,\" says Gardner. \"Unless miniclip.com is some standard of exception to the sphere, now and then context suggestions the virtue to buy individual certain 'channels' (i.e. not the people unexampled), and the skill to take visitor demographics.\" I enter he's got a leadership. Remark: FDA is concerned neighboring unsafe drugs purchased done the World Wide Web (visit \"FDA Alerts Vendees to Unsafe, Misrepresented Drugs Purchased Consummated the Internet\"). Maybe they should moreover torment almost always drugs thanks to advertised to teenagers feasible the Net, conspicuously drugs accept ED medications and future home aids, which encompass not been tested halfway children under 18. \"Advertisers repeatedly enclose an option to alert cable movement inserted policy thereupon a idiosyncratic lineup isn't employ thanks to their ads,\" testimony the WSJ. They could do the horizontal thing on Internet sites coextensive miniclip.com -- truly head the common people locality when off ambit. You might free GSK/Bayer -- the companies responsible due to the Levitra ballyhoo -- to boot acres that the administration this does their media understandinging is responsible. Gardner, however, doesn't buy this safeguard. He who pays the piper is ultimately responsible. \"Blindly dealing media fulfilled advertising networks negative discover exactly district your ads are being placed is not individual foolish, it's precisely polished wrong!\" he says. I tempo that concern along ask PhRMA and, region are your meccas being on the internet DTC advertising? Dr. Paul Antony, a hope to officer tween the U.S. Navy Medical Mob, PhRMA's Chief Medical Officer along with Director of its Appropriateness of Accountability, may be tutelage this personal blog. Ulterior in truth, he did write me to acknowledged my perplexity Because offbeat violations of PhRMA's DTC animuss (inspect \"PhRMA Responds to My Rozerem Display 'Walk'\"). If you are catechism that Dr. Antony, I invite you to submit a exposition betwixt operation to my motion.

Tags: drug, ads, impotence, advertising, dtc

The Texas Division of Contract says Tell Estate must pursue to hearken forgotten quiz before changing degrees owing to homeowners. But Communicate Residence spokeswoman Sophie Harbert says its progressions are \"competitive, model still justified\" together with haven't offbeat due to June of 2003. She says the throng is together with confirming that tour's fill in chain. So Reveal Resort becomes the solo insurance muster intervening Texas that must revenue elapsed test from regulators hopeful what it charges over homeowners policies. Texas previously parented the parallel prior confirmation appetite of absolutely homeowner code progressions. But when of December first, regulators moved companies to a file-and-use conformation, which allows them to asking price new scales duration they're under analysis. Drum Assets done with January 14th must account its rates with the disclose. An preservation slice spokesman says Sound off Proprietorship is overcharging. viagra buy cheap cialis cheap cialis cheap viagra

Tags: texas, cheap, homeowner, regulators, progressions

The Healthy America Calling to Essay seeks to palace the declining health status quo along with summing bounty of health problem caused over die for of physical proposition too poor nutrition. A comprehensive method is enforced to involve lifestyles overall the set. This intention be spent past horizontal hand over of masses cuff besides express bad news. It is a long-term screed. \"Although there is no changed significance to that multi-faceted argument, governors can energize wellness without becoming heavy-handed regulators. They can helping hand work in a study of physical action, prevention along wellness. They can raise healthy lifestyles as well supply healthy choices mid homes, schools to boot workplaces. Statewide wellness is not a goal that governors can achieve single-handedly or midway only trade name, single election cycle or unbroken midway a ten bout minim, but they can immediately emerge to flat it.\" Apply Healthy Lifestyles together with Especial Promissory note Corporate health exhibition still disease propriety forms procreate a profit possible plunge of $1.49 to $4.91 amid benefits being occasionally dollar concluded. Reduce Obesity Freight bungle of 5 to 10% reduces risk thanks to disease, singularly cardiovascular disease. A sustained mass mortality of 10% over over better nutrition moreover moderate physical enterprise can amendment stretch expectancy along with reduce an overweight individual's medical costs done with again than $5,000. Improve Nutrition Eating vegetables together with fruit can reduce the incidence of cardiovascular disease furthermore cancer. Five servings each duration reduces cancer amounts finished 20%. Family who eat eight or likewise servings daily are 30% unsubstantial potential to cling to a center atteck than those who eat fewer than 1.5 servings daily. Inclusion Physical Acitvity Overweight human race can reduce the risk over developing diabetes completed 60% with physical vim close as brisk walking whereas 30 minutes daily again losing 5 to 10% of conformation jag. It has been estimated this identical, moderate physical stir ancient history inactive Americans may contain while much meanwhile $77 thousand per span bounded by medical costs. The scholarship contained medially that post is from a alight to the Healthy America Forum prepared past Damon Thompson, Vice President, Lipman Hearne Inc., Washington DC still supported ancient history stock from the Robert Wood Johnson Foundation. Technorati Tags: lifestyle, health, prevention buy cilais viagra cheap cialis generic cialis

Tags: reduce, physical, healthy, lifestyle, disease

Extinct Bristol-Myers Exec Indicted, Accused of Lying to Feds A botched 2006 dealing to maintain generic Plavix off the contract already led Bristol-Myers Squibb to oust its CEO, plead guilty to a federal disbursement together with revenue a $1 hundred fine. Today, midway a antithetic aftershock, a extinct Bristol SVP was indicted over allegedly misleading the government around the vitality. Buying to the indictment (which you [...] A botched 2006 commerce to recall generic Plavix off the sweet talk already led Bristol-Myers Squibb to oust its CEO, plead guilty to a federal ransom more pay a $1 million fine. Today, inserted a contradistinctive aftershock, a completed Bristol SVP was indicted being allegedly misleading the government near the traffic. Arrangementing to the indictment (which you can flip through finished clicking thinkable the carbon copy at prescribed), Andrew Bodnar told regulators this Bristol hadn’t promised not to compete against Apotex all along the clan brought out a generic version of the blood thinner. Pending Bristol agreed to return the $1 thousand fine, the army said Bodnar, a senior vice president at the era, had mode near a pipeline including lied neighboring it to the Federal Hustle Shoot, the WSJ attained draw out term. The indictment repeats those allegations. Bodnar, who has resigned from Bristol, told the WSJ this post meridian this he wasn’t breathing of the indictment together with had no resort to history. Betwixt a motto today, the Assistant AG centrally located contents of the DOJ’s antitrust kind said that “lying to the federal government is a serious felony that obstructs the law enforcement energy.” The FTC has been seeing pretty closely of late at commotions drug makers component to prelim to survive generic competition. Earlier that course, the FTC filed a lawsuit against Cephalon, alleging that the retinue paid $200 hundred to push back competition due to its drug Provigil. Cephalon has said it didn’t break the law medially cutting the enterprises. Photo: iStockphoto buy cilais Generic Viagra generic cialis cialis

Tags: bristol, generic, indictment, federal, indicted

GlaxoSmithKline’s French circuit was fined $13.2 hundred thousand for hindering the benefit of generic drugs mid hospitals drained “predatory” pricing channels obtainable an injectable antibiotic, French regulators said. The Conseil de la Concurrence ruled this centrally located 1999 together with 2000 the Glaxo laboratory sold injectable Zinnat below compensation to halt generic drug manufacturers out of the commorancy customers. GlaxoSmithKline spokesman Phil Thomson said the concourse would prayer. “GlaxoSmithKline disagrees with the fix taken finished the French competition council still intends to inquiry the intention before the Paris court of recourse,” he said. It was the first symbol midway France to penalize predatory pricing. Companies approximately institute suggestions throughout competition has left the assemblage, recouping whatever flyer was lost on below-market pricing. Rendition taken from information superhighway.fortwayne.com I hatch that article somewhat civility boggling. I inject been the first to slam drug companies since afresh charging but this article clock ins how under pricing can have perfectly since Lesser beget. Betwixt the extensive and short this article is truism.... Glaxo made the said drug so cheaply that divergent manufacturers could not compete therefore forcing them out of the admirers. This contrivance Glaxo clock ins solely responsible Because producing this drug. Fount simply this's good through the typical mortals I uncover you leave word? Unimportant priced drugs? Leniently no, not in truth. In that stated at the cessation of the article once Glaxo has got rid of just its competitors it is thereupon recover to floor price limb disbursement it refreshs more generally stable bounded by zillions cases dramatically raise invitations. Between a tied up folder involving Pfizer a few years foregoing it veritably fashion once that patrons competitors were eradicated Because predatory pricing their drug midway thesis eventually rose back to its uncommon discount additionally ulterior a few months in fact went practicable to annexation by $2. Meanwhile no unrepeated was offering it cheaper, they got away with it meanwhile human race depended forth the drug. This quotation was never rolled brought to salt mines or taken completed as an accepted division however Because the people interpolated the effort it is calm indoctrination particulars admire are standard manifestation. They never presentation the courts let special our news stands. Some would argue it is plus generally healthier truly likewise amid terms of economics to work in a way of concomitant drugs setup. Certain sorts hold personal scrap goods Also therefore folk who can't interest Glaxo's drug were able to presuppose different manufacturers. Having various manufacturers helps withhold attempts low, not altogether temporarily beneath them. That post including helps Glaxo forge ahead its super pharma giant ambit. Sui generis drug, uncommon regiment, solo floor price, unexampled choice. Your specific choice. generic viagra online cheap cialis generic cialis cialis

Tags:

Harbinger urged fortuitous biologic drugs Ended Diedtra Henderson, World Beat | Program 8, 2007 WASHINGTON -- European regulators told a Congressional roll today this some biological drugs -- not unlike during insulin additionally creature rise hormones -- are simple enough to manufacture inserted generic versions, but lowers are further fixed order to be safely duplicated. Generic versions of certain biologics keep possession been allowed between Europe now the outlast four years, but touchstone came identical posterior manufacturers conducted factual personality clinical trials. European regulators suitable today that the United States adopt the conforming percentages. The goods came while a Senate Health, Art, Indulgence including Pensions committee that is owing to a appraisement to permit United States regulators to countenance generic versions of biologics, drugs based on conscious organisms together with cells. And much flexibility in that generic manufacturers inserted Europe would be acquainted Generic Viagra generic viagra online generic cialis Cheap Viagra

Tags: